Key Takeaways
- • Blackstone and TPG have completed their acquisition of Hologic (Nasdaq: HOLX), a global leader in women's health diagnostics and medical devices, marking a significant transaction in the healthcare technology sector.
- • The deal represents a strategic consolidation of women's health capabilities under joint ownership by two major alternative asset managers, combining their operational and financial resources.
- • Hologic's market position in women's health—spanning diagnostic imaging, surgical tools, and related medical technologies—becomes a controlled asset within the private equity portfolios of Blackstone and TPG.
- • The completion signals continued appetite from leading private equity firms for healthcare and life sciences assets, particularly in specialized segments with stable revenue streams and recurring customer bases.
Summary
Blackstone and TPG have successfully completed their acquisition of Hologic, Inc. (Nasdaq: HOLX), a publicly-traded company specializing in women's health technologies and diagnostic solutions. The transaction closes a significant healthcare-sector deal for two of the world's largest alternative asset managers, consolidating Hologic's operations under their joint ownership.
Hologic is recognized as a global leader in women's health, operating across multiple segments including diagnostic imaging, surgical instruments, and related medical devices. The company's portfolio serves healthcare providers and patients globally, with established market positions in breast health, gynecological care, and related diagnostic categories. The acquisition removes Hologic from public markets, converting it to a privately-held entity managed by the Blackstone and TPG investment teams.
The completion of this transaction underscores the continued strategic interest from mega-cap private equity firms in healthcare and life sciences assets. Healthcare companies with diversified revenue bases, recurring customer relationships, and stable cash flows have remained attractive acquisition targets for institutional investors seeking both growth and defensive characteristics within their portfolios.
With the deal now closed, Blackstone and TPG will oversee Hologic's operations, capital allocation, and strategic direction. The partnership between these two leading alternative asset managers combines significant operational expertise, global distribution networks, and financial resources typically deployed in large-scale platform acquisitions. The specific transaction terms and valuation were not disclosed in available reporting.
Hologic is recognized as a global leader in women's health, operating across multiple segments including diagnostic imaging, surgical instruments, and related medical devices. The company's portfolio serves healthcare providers and patients globally, with established market positions in breast health, gynecological care, and related diagnostic categories. The acquisition removes Hologic from public markets, converting it to a privately-held entity managed by the Blackstone and TPG investment teams.
The completion of this transaction underscores the continued strategic interest from mega-cap private equity firms in healthcare and life sciences assets. Healthcare companies with diversified revenue bases, recurring customer relationships, and stable cash flows have remained attractive acquisition targets for institutional investors seeking both growth and defensive characteristics within their portfolios.
With the deal now closed, Blackstone and TPG will oversee Hologic's operations, capital allocation, and strategic direction. The partnership between these two leading alternative asset managers combines significant operational expertise, global distribution networks, and financial resources typically deployed in large-scale platform acquisitions. The specific transaction terms and valuation were not disclosed in available reporting.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.